Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies

Sponsored by UCB

Feb 19, 2025 11:00 am

Download or View PDF

Presentation

Coates RNBL2025

Laura C. Coates, M.D.

Author(s):

Philip J. Mease,William Tillett, Maarten de Wit, Laure Gossec, M. Elaine Husni, Fabian Proft, Barbara Ink, Rajan Bajracharya, Jason Coarse, Jérémy Lambert, Laura C. Coates,Alice B. Gottlieb

Abstract or description:

This study aimed to report the impact of longer-term bimekizumab (BKZ) treatment up to 2 years on patient-reported pain and fatigue in patients with psoriatic arthritis (PsA) who were biologic disease-modifying antirheumatic drug (bDMARD)-naïve or had inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR).

These studies were funded by UCB. All costs associated with development of this presentation were funded by UCB.

More Virtual Posters

Time to Clinical Response Poster

Time to Clinical Response to Secukinumab Across Disease Domains Among Patients With Psoriatic Arthritis: a Pooled Post Hoc Analysis of 4 Phase 3 Trials

Secukinumab Retention and Effectiveness in Patients with Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: 5-Year Final Results of a Prospective Real-World Study

AbbVie March 2025

Real-world outcomes in patients with RA remaining on first-line TNFi

AbbVie March 2025

Long-term maintenance of response of an IL-23i in PsA

Presentation

Coates RNBL2025

Laura C. Coates, M.D.

Author(s):

Philip J. Mease,William Tillett, Maarten de Wit, Laure Gossec, M. Elaine Husni, Fabian Proft, Barbara Ink, Rajan Bajracharya, Jason Coarse, Jérémy Lambert, Laura C. Coates,Alice B. Gottlieb

Abstract or description:

This study aimed to report the impact of longer-term bimekizumab (BKZ) treatment up to 2 years on patient-reported pain and fatigue in patients with psoriatic arthritis (PsA) who were biologic disease-modifying antirheumatic drug (bDMARD)-naïve or had inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR).

These studies were funded by UCB. All costs associated with development of this presentation were funded by UCB.

×